" class="no-js "lang="en-US"> Resources Archives - Page 5 of 6 - Medtech Alert
Saturday, October 11, 2025

Sort by:

Date

Top Post

Impact Therapeutics Announces Completion of Series D1 Financing

IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics […]

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health

Curebase, a company committed to democratizing access to clinical studies, and Blue Note Therapeutics, a prescription […]

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration […]

Exosome-based Company Raised 5 M€ for the Development of Its New Biomedicine and Vaccines

Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that […]

Vygon Acquires Macatt Medica, Peruvian Distributor of Single-use Medical Devices

Vygon, a specialist single-use medical devices group, today announces the acquisition of Macatt Medica, a […]

NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech […]

AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer

AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. […]

Tollys and Gustave Roussy Enter into New Research Agreement

Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like […]

CELLINK Launches the BIO CELLX, a First of its Kind Biodispensing Platform to Automate 3D Cell Culture

Today CELLINK, A BICO Company, launched the BIO CELLX a novel system that automates 3D […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more